The Analyst Landscape: 7 Takes On TScan Therapeutics
Portfolio Pulse from Benzinga Insights
Analysts' ratings for TScan Therapeutics (NASDAQ:TCRX) vary from bullish to bearish, with a majority being bullish. The average 12-month price target is $12.43, reflecting a slight increase. Despite a significant decline in revenue, the company shows strong financial health in other metrics.
June 04, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts' ratings for TScan Therapeutics (NASDAQ:TCRX) are predominantly bullish, with an average 12-month price target of $12.43. Despite a significant revenue decline, the company shows strong financial health in other metrics.
The majority of analysts have a bullish outlook on TScan Therapeutics, with a slight increase in the average price target. This positive sentiment is likely to boost the stock price in the short term. However, the significant revenue decline may temper some of the optimism.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100